Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Barry Paul, MDMS, Myra Robinson, MSPH, Kristen Cassetta, Daniel Slaughter, Jordan Robinson, Ami P Ndiaye, NP, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA, Shebli Atrash, MD

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-141637

Published: 2020

Journal Articles

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sagar Lonial, MD FACP, Peter M. Voorhees, MD, Simona Degli Esposti, MD, Ira Gupta, MD, Joanna Opalinska, MD, Sandhya Sapra, PhD, Boris Gorsh, PharmD, Zangdong He, PhD, David M Kleinman, MD, Debra Schaumberg, OD, MPH, ScD, Angely Loubert, PharmD, MSc, Juliette Meunier, MSc, Antoine Regnault, PhD, Laurie Eliason, MPH

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-140013

Published: 2020

Journal Articles

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Barry Paul, MDMS, James Symanowski, PhD, Paul Osipoff, Sarah Norek, BSN, RN, Ami P Ndiaye, NP, Jordan Robinson, Shebli Atrash, MD, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-141623

Published: 2020

Journal Articles

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Shebli Atrash, MD, Myra Robinson, MSPH, Barry Paul, MDMS, Sarah Norek, BSN, RN, David M. Foureau, PhD, Carrie Ann Syfert, BSN, RN, Ami P Ndiaye, NP, James T Symanowski, PhD, Jordan Robinson, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141562

Published: 2020

Journal Articles

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, MD, Anita D'Souza, MD MS, Nina Shah, MD, Peter M. Voorhees, MD, Ben Buelow, MD PhD, Ravi Vij, MBBS, Shaji K. Kumar, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-139893

Published: 2020

Journal Articles

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Sara Bringhen, Peter M. Voorhees, MD, Torben Plesner, MD DSc, Ulf-Henrik Mellqvist, MD PhD, Brandi Reeves, MD, Pieter Sonneveld, Catriona Byrne, RN, Eva Nordström, MSc, Johan Harmenberg, MD PhD, Jakob Obermüller, MSc, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 1839.

https://doi.org/10.1182/blood-2019-124828

Published: 2019

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Molecular Characterization By Immune Profiling of Paired Blood and Bone Marrow in Multiple Myeloma and Its Precursor States

Manisha Bhutani, MD, David M. Foureau, PhD, Nury M Steuerwald, PhD, Sally Trufan, Fei Guo, PhD, Katherine Rigby, Elise Tjaden, Alicia Hamilton, Marina Leonidas, Aarin Berlin, Laura Johnson, Jordan Williams, Shebli Atrash, Ami P Ndiaye, NP, James Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2018-99-118281

Published: 2018

Journal Articles

Risk Factors for Thromboembolism (TE) in Multiple Myeloma (MM) Patients (pts) Treated with Immunomodulatory Agents (IMiDs) Plus Dexamethasone (dex)

Jai N Patel, PharmD, BCOP, Megan Helena Jagosky, MD, Myra M Robinson, MSPH, Daniel Slaughter, Justin Arnall, PharmD, CPP, BCOP, Ashley Matusz-Fisher, MD, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 4814.

https://doi.org/10.1182/blood-2018-99-118283

Published: 2018

Journal Articles

Prognostic Significance of Tracking Dynamic Changes in Positron Emission Tomography (PET) Scan Pre and Post Autologous Stem Cell Transplant (ASCT)

Shebli Atrash, Myra M Robinson, MSPH, Manisha Bhutani, MD, Daniel Slaughter, Issam S. Hamadeh, PharmD, Peter M. Voorhees, MD, Jill Eddy, Lauren Minard, Reed Freind, Jordan Robinson, NDaiye AMI, Chelsea Sprouse, James Symanowski, PhD, Maham Khan, Belinda Rene Avalos, MD, Rajesh Banderudrappagari, Justin Arnall, PharmD, CPP, BCOP, Edward A. Copelan, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 5582.

https://doi.org/10.1182/blood-2018-99-118099

Published: 2018

Journal Articles

Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients

David M. Foureau, PhD, Manisha Bhutani, MD, Myra Robinson, MS, Fei Guo, PhD, Duy Pham, Shelley Force Aldred, Ben Buelow, MD PhD, Katherine Rigby, Elise Tjaden, Marina Leonidas, Shebli Atrash, Ami P Ndiaye, NP, James Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2018-99-118881

Published: 2018

Journal Articles

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Issam S. Hamadeh, PharmD, Justin Arnall, Pharm.D., Ekaterina Kachur, PharmD, Allison Martin, PharmD, Megan Helena Jagosky, MD, Reed Friend, MD, Shebli Atrash, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2018-99-118737

Published: 2018

Journal Articles

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Blood (2018) 132 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2018-99-113467

Published: 2018

Journal Articles

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Parameswaran Hari, MBBS, MD, Mark A. Schroeder, MD, James R Berenson, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Peter M. Voorhees, MD, Hisaki Fujii, Zhao Yang, Francesco Galimi, MDPhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 803.

https://doi.org/10.1182/blood-2018-99-112610

Published: 2018

Journal Articles

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J Costa, MD PhD, Yana Lutska, PharmD, Daniela Hoehn, MDPhD, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 151.

https://doi.org/10.1182/blood-2018-151

Published: 2018

Journal Articles

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Sara Bringhen, MD, Peter M. Voorhees, MD, Torben Plesner, MD, Claudia Paba-Prada, MD, Ulf-Henrik Mellqvist, MD, Jeffrey A Zonder, MD, Brandi Reeves, MD, Antonio Palumbo, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Eva Nordstrom, MSc, MBA, Hanan Zubair, MSc, Jakob Lindberg, MD PhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3150.

https://doi.org/10.1182/blood.V130.Suppl_1.3150.3150

Published: 2017

Journal Articles

Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma

Myra M Robinson, MSPH, Shebli Atrash, Taylor Brown, BS, MS, Jared G Block, MD, Edward H Lipford, MD, Elton T Smith, MD, Reed Friend, MD, Amanda Aneralla, Alankrita Taneja, MD, Qing Zhang, PhD, David M Foureau, PhD, Chelsea Sprouse, Ami Ndiaye, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD, Manisha Bhutani, MD

Blood (2017) 130 (Supplement 1): 4348.

https://doi.org/10.1182/blood.V130.Suppl_1.4348.4348

Published: 2017

Journal Articles

Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

David M Foureau, PhD, Manisha Bhutani, MD, Qing Zhang, PhD, Myra M Robinson, MSPH, Adina Wynn, Nury M Steuerwald, PhD, Lawrence J Druhan, PhD, Fei Guo, PhD, Katherine Rigby, Mitchell Turner, Reed Friend, MD, Shebli Atrash, Chelsea Sprouse, Ami Ndiaye, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 1817.

https://doi.org/10.1182/blood.V130.Suppl_1.1817.1817

Published: 2017

Journal Articles

Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma

Shebli Atrash, Myra M Robinson, MSPH, Amanda Aneralla, Taylor Brown, BS, MS, Reed Friend, MD, Chelsea Sprouse, Ami Ndiaye, Qing Zhang, PhD, Edward H Lipford, MD, Jared G Block, MD, Elton T Smith, MD, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD, Manisha Bhutani, MD

Blood (2017) 130 (Supplement 1): 1779.

https://doi.org/10.1182/blood.V130.Suppl_1.1779.1779

Published: 2017

NARROW

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Molecular Characterization By Immune Profiling of Paired Blood and Bone Marrow in Multiple Myeloma and Its Precursor States

Risk Factors for Thromboembolism (TE) in Multiple Myeloma (MM) Patients (pts) Treated with Immunomodulatory Agents (IMiDs) Plus Dexamethasone (dex)

Prognostic Significance of Tracking Dynamic Changes in Positron Emission Tomography (PET) Scan Pre and Post Autologous Stem Cell Transplant (ASCT)

Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma

Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only